ImCheck Therapeutics, a Marseille, France-based biotech company, closed a $53 million (€48 million) Series B financing round.
The round was co-led by Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), and Bpifrance through its InnoBio 2* and Large Venture funds and joined by new investors Wellington Partners, Agent Capital and Alexandria Venture Investments and existing backers Life Sciences Partners (LSP), Gimv, Idinvest Partners, Kurma Partners and Boehringer Ingelheim Venture Fund.
ImCheck’s Board of Directors will transition to include Michael Baran from Pfizer Ventures, Thibaut Roulon from Bpifrance, Regina Hodits from Wellington, Rémi Droller from Kurma, Vincent Brichard from LSP, Bram Vanparys from Gimv, Debasish Roychowdhury as independent Chairman and Pierre d’Epenoux, CEO of ImCheck.
The proceeds of the Series B will be used to fund the initial clinical trial for ImCheck’s monoclonal antibody ICT01, to further expand the company’s broad pipeline of immunomodulators targeting the butyrophilins super-family and to bring additional immuno-oncology antibody programs into the clinic.
Led by Pierre d’Epenoux, Chief Executive Officer, ImCheck Therapeutics is developing a first-in-class antibody to activate gamma delta (gd) T cells in a range of cancer indications and a portfolio of novel immunotherapies for the treatment of cancer and autoimmune diseases.
The company benefits from support from Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille Université), a worldwide leader in gd T cells and butyrophilins research.